TBCA

• Description:

  TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Casein Kinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tbca.html

• Concentration:

  10mM

• Purity:

  99.45

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC (/C=C/C1=C (C (Br) =C (Br) C (Br) =C1) Br) =O

• Molecular Formula:

  C9H4Br4O2

• Molecular Weight:

  463.74

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8 (1) :129-139.|[2]Ryu SY, Kim S. Evaluation of CK2 inhibitor (E) -3- (2,3,4,5-tetrabromophenyl) acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720 (1-3) :391-400.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CK2

• CAS Number:

  934358-00-6